Non-viral vectors for gene-based therapy

被引：2519

作者：

Yin, Hao ^{[1
]}

Kanasty, Rosemary L. ^{[1
,2
]}

Eltoukhy, Ahmed A. ^{[1
]}

Vegas, Arturo J. ^{[1
,3
]}

Dorkin, J. Robert ^{[1
,4
]}

Anderson, Daniel G. ^{[1
,2
,3
,5
,6
]}

机构：

[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA

[2] MIT, Dept Chem Engn, Cambridge, MA 02142 USA

[3] Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA

[4] MIT, Dept Biol, Cambridge, MA 02142 USA

[5] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA

[6] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA

来源：

NATURE REVIEWS GENETICS | 2014年 / 15卷 / 08期

基金：

美国国家科学基金会; 美国国家卫生研究院;

关键词：

IN-VIVO DELIVERY; PLASMID-LIPID PARTICLES; MODIFIED MESSENGER-RNA; TRANSGENE EXPRESSION; TARGETED DELIVERY; SLEEPING-BEAUTY; VIRAL VECTORS; ADMINISTERED SIRNA; NONHUMAN-PRIMATES; SYSTEMIC DELIVERY;

D O I：

10.1038/nrg3763

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Gene-based therapy is the intentional modulation of gene expression in specific cells to treat pathological conditions. This modulation is accomplished by introducing exogenous nucleic acids such as DNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides. Given the large size and the negative charge of these macromolecules, their delivery is typically mediated by carriers or vectors. In this Review, we introduce the biological barriers to gene delivery in vivo and discuss recent advances in material sciences, nanotechnology and nucleic acid chemistry that have yielded promising non-viral delivery systems, some of which are currently undergoing testing in clinical trials. The diversity of these systems highlights the recent progress of gene-based therapy using non-viral approaches.

引用

页码：541 / 555

页数：15

共 159 条

[11] Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120
[12] Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles
Bartlett, Derek W.
Davis, Mark E.
[J]. BIOTECHNOLOGY AND BIOENGINEERING, 2008, 99 (04) : 975 - 985
[13] Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors
Baum, C
Kustikova, O
Modlich, U
Li, ZX
Fehse, B
[J]. HUMAN GENE THERAPY, 2006, 17 (03) : 253 - 263
[14] STEALTH ME.PEG-PLA NANOPARTICLES AVOID UPTAKE BY THE MONONUCLEAR PHAGOCYTES SYSTEM
BAZILE, D
PRUDHOMME, C
BASSOULLET, MT
MARLARD, M
SPENLEHAUER, G
VEILLARD, M
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) : 493 - 498
[15] Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery
Bellocq, NC
Pun, SH
Jensen, GS
Davis, ME
[J]. BIOCONJUGATE CHEMISTRY, 2003, 14 (06) : 1122 - 1132
[16] Immune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N
GarciaCozar, FJ
Boissier, MC
[J]. GENE THERAPY, 2004, 11 (Suppl 1) : S10 - S17
[17] Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Boch, Jens
Scholze, Heidi
Schornack, Sebastian
Landgraf, Angelika
Hahn, Simone
Kay, Sabine
Lahaye, Thomas
Nickstadt, Anja
Bonas, Ulla
[J]. SCIENCE, 2009, 326 (5959) : 1509 - 1512
[18] Viral vectors: from virology to transgene expression
Bouard, D.
Alazard-Dany, N.
Cosset, F-L
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (02) : 153 - 165
[19] A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE
BOUSSIF, O
LEZOUALCH, F
ZANTA, MA
MERGNY, MD
SCHERMAN, D
DEMENEIX, B
BEHR, JP
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) : 7297 - 7301
[20] Gene delivery with tow molecular weight linear polyethytenimines
Breunig, M
Lungwitz, U
Liebl, R
Fontanari, C
Klar, J
Kurtz, A
Blunk, T
Goepferich, A
[J]. JOURNAL OF GENE MEDICINE, 2005, 7 (10) : 1287 - 1298

← 1 2 3 4 5 6 7 8 9 10 →